IH636 Grape Seed Extract in Treating Hardening of Breast Tissue in Women Who Have Undergone Radiation Therapy for Early Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.

Verified September 2002 by National Cancer Institute (NCI). Recruitment status was Active, not recruiting

First Received on July 8, 2002. Last Updated on May 9, 2009 History of Changes

Sponsor:	Royal Marsden NHS Foundation Trust
Information provided by:	National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:	NCT00041223

Purpose

RATIONALE: IH636 grape seed extract may lessen hardening of breast tissue caused by radiation therapy and may help patients live more comfortably.

PURPOSE: Randomized phase II trial to study the effectiveness of IH636 grape seed extract in treating hardening of breast tissue in women who have undergone radiation therapy for early breast cancer.

Condition	Intervention	Phase
Breast Cancer Radiation Fibrosis	Dietary Supplement: IH636 grape seed proanthocyanidin extract	Phase II

Study Type:	Interventional
Study Design:	Allocation: Randomized Masking: Double-Blind Primary Purpose: Supportive Care
Official Title:	Double-Blind, Placebo-Controlled, Randomized Phase II Trial of IH636 Grape Seed Proanthocyanidin Extract (GSPE) in Patients With Adverse Effects of High Dose Breast Radiotherapy

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer Cancer

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Study Start Date:

September 2002

Detailed Description:

OBJECTIVES:

Determine the efficacy of IH636 grape seed proanthocyanidin extract for the treatment of radiation-induced fibrosis after high-dose radiotherapy in women with a history of early breast cancer.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified according to time since prior radiotherapy. Patients are randomized to 1 of 2 arms.

Arm I: Patients receive oral IH636 grape seed proanthocyanidin extract three times daily for 6 months.
Arm II: Patients receive an oral placebo three times daily for 6 months. Patients are followed at 6 months.

PROJECTED ACCRUAL: A total of 72 patients (48 for arm I and 24 for arm II) will be accrued for this study.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

History of early breast cancer
- T1-T3, N0-N1, M0
No evidence of cancer recurrence
Palpable breast induration due to prior radiotherapy
Hormone receptor status:
- Not specified

PATIENT CHARACTERISTICS:

Age:

18 and over

Sex:

Female

Menopausal status:

Not specified

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

Not specified

Hepatic:

Not specified

Renal:

Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

Not specified

Endocrine therapy:

Not specified

Radiotherapy:

See Disease Characteristics
At least 2 years since prior radiotherapy

Surgery:

Not specified

Other:

At least 3 months since prior dietary supplementation containing IH636 grape seed proanthocyanidin extract over 50 mg per day

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00041223

Locations

United Kingdom
Royal Marsden Hospital
Sutton, England, United Kingdom, SM2 5PT

Sponsors and Collaborators

Royal Marsden NHS Foundation Trust

Investigators

Study Chair:

John R. Yarnold, MD, FRCR

Royal Marsden NHS Foundation Trust

More Information

Additional Information:

Clinical trial summary from the National Cancer Institute's PDQ® database This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier:	NCT00041223 History of Changes
Other Study ID Numbers:	CDR0000069454, RMNHS-GRAPE-1991, RMNHS-1991, EU-20209
Study First Received:	July 8, 2002
Last Updated:	May 9, 2009
Health Authority:	United States: Federal Government

Keywords provided by National Cancer Institute (NCI):

radiation fibrosis
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer

Additional relevant MeSH terms:

Breast Neoplasms
Fibrosis
Radiation Pneumonitis
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Pathologic Processes
Lung Diseases, Interstitial
Lung Diseases
Respiratory Tract Diseases
Lung Injury
Radiation Injuries
Wounds and Injuries

Proanthocyanidin
Procyanidin
Grape Seed Extract
Antioxidants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protective Agents
Physiological Effects of Drugs
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Therapeutic Uses
Antineoplastic Agents, Phytogenic
Antineoplastic Agents

ClinicalTrials.gov processed this record on February 09, 2012